Trial
NCT02520427
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Relapsed/Refractory AML
Intervention
AMG 330
Why stopped
Amgen strategic business decision to cancel following portfolio review, re-prioritization.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-31